Drugs / BT-007
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05554575 | Oct 2022 → Sep 2024 | T-lymphoblastic lymphoma | Bioceltech Therapeutics, Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BT-007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05554575 ↗ |
| Modality | Cell therapy | “BT-007 CD7 CAR-T cells” NCT05554575 ↗ |
| Target | CD7 | “T cells expressing CD7 chimeric antigen receptors” NCT05554575 ↗ |